Introduction
============

Changes in macular thickness measurements in neovascular age-related macular degeneration (nAMD) are thought to reflect disease activity, and can be used to guide treatment with antiangiogenic agents.[@b1-opth-11-2121] Both spectral-domain optical coherence tomography (SD-OCT) and the more recently introduced swept-source optical coherence tomography (SS-OCT) have onboard segmentation algorithms that deliver automated retinal thickness measurements. Agreement between OCT derived macular thickness measurements is critical for monitoring of patients if these modalities are to be used interchangeably. This prospective cross-sectional study sought to determine the limits of agreement between SD-OCT (Spectralis; Heidelberg Engineering) and SS-OCT (DRI OCT-1 Atlantis; Topcon Medical Systems) in patients with nAMD.

Methods
=======

This study formed part of the Distance of Choroid Study (DOCS) at Moorfields Eye Hospital, London in 2014. All subjects gave written informed consent prior to inclusion in the study. The study was approved by the local ethics committee (NRES Committee, South East Coast, Surrey) and adhered to the tenets set forth in the Declaration of Helsinki. Subjects aged 50--90 years with subfoveal choroidal neovascularization secondary to nAMD were included. Exclusion criteria included media opacity, previous ocular surgery (other than cataract surgery), significant ocular comorbidity, and diabetes mellitus. All patients underwent three Spectralis scans and three DRI OCT-1 scans in the same imaging session. The Spectralis scan was a macular volume scan consisting of a 25-line horizontal-line scan (512 A scan per B scan) in enhanced depth-imaging mode. The DRI OCT-1 scan consisted of a 12×9 mm raster scan centered on the fovea. Automated retinal thickness measurements of the Early Treatment Diabetic Retinopathy Study were obtained using proprietary software on both SD-OCT (version 3.1) and SS-OCT (version 9.30).

Results
=======

A total of 36 eyes of 36 patients with nAMD were included in the study. Subject characteristics are summarized in [Table 1](#t1-opth-11-2121){ref-type="table"}. Bland--Altman analysis showed low agreement between OCT-derived macular thickness measurements, with mean difference ranging from 18.2 μm (A7) to 77.6 μm (A2) ([Figure 1](#f1-opth-11-2121){ref-type="fig"}). The 95% limits of agreement of the central macular subfield (A1) were −20.5 μm to 156.3 μm. There was a correlation between the magnitude of the retinal thickness measurement and the degree of variation between SD-OCT and SS-OCT for the A1 subfield (Spearman's correlation coefficient 0.59, *P*=0.02), suggesting that the variation in OCT derived metrics was perhaps more evident in those with more active disease. Given this association, it is possibly more appropriate to express the limits as a ratio after logarithmic transformation (95% limits of agreement 0.97--1.74), indicating that the SD-OCT measurements can be between 3% smaller and 74% larger than SS-OCT central macular subfield-thickness measurements.[@b2-opth-11-2121]

Discussion
==========

This analysis suggests there is surprisingly limited level of agreement between SD-OCT- and SS-OCT-derived retinal thickness measurements in subjects with nAMD included in our study. Alteration in foveal structure due to developing choroidal neovascularization, changes in foveal centration and segmentation error may affect retinal thickness measurements in nAMD.[@b3-opth-11-2121]--[@b5-opth-11-2121] The Spectralis and DRI OCT function at different imaging-light wavelengths (840 nm and 1,050 nm, respectively) with different spatial resolution (7×14 μm and 8×20 μm, respectively). Differences in segmentation algorithms, particularly in the location of the inner retinal boundary, have the potential to alter automated retinal thickness measurements.[@b6-opth-11-2121] Further analysis with a larger study population is required to evaluate the disparity between retinal thickness measurements. We suggest that the use of absolute retinal thickness measurements in nAMD can only be interpreted in the context of the OCT technology used. Differences in the central macular subfield measurements appeared greatest at larger retinal thicknesses, where disease activity was presumably higher. Clinicians should be aware of this variability, and should consider utilization of a single form of OCT during monitoring of patients with nAMD to prevent conflation of variation in disease activity and different forms of OCT technology.
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![Bland-Altman analysis comparing the mean difference between spectral-domain and swept source optical coherence tomography macular thickness measurements in neovascular age related macular degeneration.\
**Notes:** Mean difference (bold line) and 95% limits of agreement (LoA; dotted lines) between mean automated retina thickness measurements of Early Treatment Diabetic Retinopathy Study (ETDRS) subfields (**A**) A1 central: mean 67.9±45.1 μm; LoA: −20.5 μm to 156.3 μm; (**B**) A2 inner superior: mean 77.6±47.1 μm; LoA −14.6 μm to 169.9 μm; (**C**) A3 inner temporal: mean 67.7±54.5 μm; LoA: −39.0 μm to 174.5 μm; (**D**) A4 inner inferior: mean 75.0±46.9 μm; LoA: −18.9 μm to 167.0 μm; (**E**) A5 inner nasal: mean 74.9±41.0 μm; LoA: −5.4 μm to 155.1 μm; (**F**) A6 outer superior: mean 35.1±19.4 μm; LoA: −2.9 μm to 73.1 μm; (**G**) A7 outer temporal: mean 18.2±36.3 μm; LoA: −52.9 μm to 89.3 μm; (**H**) A8 outer inferior: mean 28.7±15.4 μm; LoA: −1.4 μm to 58.8 μm; (**I**) A9 outer nasal: mean 29.8±40.4 μm; LoA: −49.4 μm to 108.9 μm.](opth-11-2121Fig1){#f1-opth-11-2121}

###### 

Subject characteristics of patients with neovascular age-related macular degeneration

  Subject characteristics                                                                                               
  --------------------------------------------------------------------------------------------------------------------- -----------
  Age (years)                                                                                                           71.2±9.4
  Sex (n, % total)                                                                                                      
   Male                                                                                                                 22 (61.1)
   Female                                                                                                               14 (38.9)
  Laterality (n, % total)                                                                                               
   Left                                                                                                                 23 (63.9)
   Right                                                                                                                13 (36.1)
   Visual acuity (ETDRS letter score)                                                                                   63.5±19.2
  Lens status (n, % total)                                                                                              
   Phakic                                                                                                               27 (75)
   Pseudophakic                                                                                                         9 (25)
  Lesion size, mm^2^ (mean disk area ± SD)                                                                              1.2±0.8
  Lesion type (n, % total)                                                                                              
   Classic                                                                                                              15 (41.7)
   Occult                                                                                                               21 (58.3)
  Antiangiogenic treatment[\*](#tfn1-opth-11-2121){ref-type="table-fn"} history (over previous 6 months) (n, % total)   34 (94.4)
   Ranibizumab                                                                                                          28 (77.9)
   Aflibercept                                                                                                          6 (16.7)
   No previous treatment                                                                                                2 (5.6)
  Mean number of intravitreal injections (over previous 6 months)                                                       2.4

**Notes:**

Treatment with anti-VEGF agents. Data are presented as mean ± SD unless otherwise specified.

**Abbreviation:** ETDRS, Early Treatment Diabetic Retinopathy Study.
